Articles From: NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine to Neptune and BlueOcean Sign Licensing Agreement


NEW YORK, Oct.
Sign-up for NeoStem Ranked as One of the Fastest Growing Companies in New York City investment picks
NEW YORK, Jan.
Sign-up for NeoStem Receives Drug Manufacture License for Irvine Facility investment picks
NEW YORK, Nov.
Sign-up for NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014 investment picks
NEW YORK, Nov.
Sign-up for NeoStem to Present at Multiple Conferences This Week investment picks
NEW YORK, Nov.
Sign-up for NeoStem to Present at Multiple November Conferences investment picks
SAN DIEGO, Dec.
Sign-up for Neothetics Announces Closing of Upsized Initial Public Offering investment picks
SAN DIEGO, Nov.
Sign-up for Neothetics Prices Initial Public Offering investment picks
NASDAQ: NVCN TSX: NVC VANCOUVER , Dec.
Sign-up for Neovasc Announces Treatment of First Patient in TIARA-I Clinical Trial investment picks
NASDAQ: NVCN TSX: NVC VANCOUVER , Nov.
Sign-up for Neovasc to Present at Three Upcoming Investor Conferences in November investment picks
Neovasc to Ring Closing Bell at Nasdaq Canada NewsWire NASDAQ: NVCN TSX: NVC VANCOUVER , Jan.
Sign-up for Neovasc to Ring Closing Bell at Nasdaq investment picks
NASDAQ: NVCN TSX: NVC VANCOUVER , Jan.
Sign-up for Neovasc to Ring Closing Bell at Nasdaq investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank.
Sign-up for NephroGenex Announces Closing of $12 Million Term Loan Facility investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its third quarter 2014 financial results on Wednesday, November 12, 2014 after the U.S. financial markets close.
Sign-up for NephroGenex Announces Date of Conference Call to Discuss Third Quarter 2014 Financial Results investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin.
Sign-up for NephroGenex Announces Positive Results for QT Study of Pyridorin investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin ® in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment.
Sign-up for NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic Nephropathy investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2014.
Sign-up for NephroGenex Reports Third Quarter 2014 Financial Results investment picks
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company and meet with investors at the Bio-Europe ® 2014 healthcare conference in Frankfurt, Germany.
Sign-up for NephroGenex to Participate in Two Healthcare Conferences in November investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company at the Noble Financial Capital Markets Eleventh Annual Equity Conference in Sandpiper, Florida.
Sign-up for Nephrogenex to Present at the Noble Financial Capital Markets Equity Conference investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced the presentation of the novel design of its Phase 3 Pyridorin PIONEER clinical program at the American Society of Nephrology (ASN) Kidney Week meeting held here November 11-16, 2014.
Sign-up for NephroGenex, Inc. Announces Presentation at the American Society of Nephrology’s Kidney Week 2014 investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- There are a few stocks that are expected to see action on Wednesday.
Sign-up for NephroGenex, MiMedx in focus for Wednesday investment picks
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today the successful completion of its rights offering.
Sign-up for Nephros Announces Successful Completion of $3 Million Rights Offering investment picks
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today announced that the Company's Board of Directors has appointed Paul A.
Sign-up for Nephros Appoints Paul A. Mieyal as Acting Chief Executive Officer and Daron Evans as Chairman of the Board of Directors investment picks
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today provided an update on its operations and strategy.
Sign-up for Nephros Provides Corporate Update investment picks
LAVAL, Quebec, Oct.
Sign-up for Neptune and BlueOcean Sign Licensing Agreement investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine to Neptune and BlueOcean Sign Licensing Agreement
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent